Brewin Dolphin Wealth Management’s Pacific Biosciences PACB Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$3K	Buy	+760	New	+$4.62K	﹤0.01%	321

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Brewin Dolphin Wealth Management's PACB Position: Q2 2022 in Review

Brewin Dolphin Wealth Management opened a new position in Pacific Biosciences (PACB) in Q2 2022: 760 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #321 among its holdings.

229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

Brewin Dolphin Wealth Management held 760 shares of Pacific Biosciences worth $3K as of Q2 2022.
Pacific Biosciences was a new Brewin Dolphin Wealth Management position in Q2 2022.
Pacific Biosciences made up ﹤0.01% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #321 holding.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.